62nd ASH Annual Meeting and Exposition: 603. Oncogenes and Tumor Suppressors: Poster III

Oral and Poster Abstracts
Poster

ALL, AML, apoptosis, Biological, HSCs, Leukemia, Diseases, Lymphoma (any), cell regulation, Combinations, Therapies, MDS, Non-Hodgkin Lymphoma, Biological Processes, DLBCL, MPN, Immune Disorders, Technology and Procedures, Cell Lineage, Lymphoid Malignancies, Clinically relevant, genomics, Myeloid Malignancies, NK cells, hematopoiesis, Proliferative disorders, RNA sequencing, pathogenesis, WGS, pathways

2770

Recurrent Mutations of the C-C Motif Chemokine Ligand 22 (CCL22) Define a Distinct Subgroup of Chronic Lymphoproliferative Disorder of NK Cells (CLPD-NK)

Constance Baer, PhD¹, Shunsuke Kimura, MD, PhD²^*, Ilaria Iacobucci³^*, David J Feith, BS, PhD⁴^*, Wencke Walter, PhD¹^*, Manja Meggendorfer, PhD¹, Thomas L. Olson, PhD⁵^*, Aakrosh Ratan, PhD⁶^*, Martha-Lena Müller, PhD¹^*, Mitra Rana⁷^*, Chunxu Qu, PhD²^*, Ravi Kalathur⁷^*, Claudia Haferlach, MD¹, Wolfgang Kern, MD¹, Thomas P. Loughran Jr., MD⁴, Charles G Mullighan, MBBS, MD² and Torsten Haferlach, MD¹

¹MLL Munich Leukemia Laboratory, Munich, Germany
²Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
³Department of Pathology, St. Jude Children´s Research Hospital, Memphis, TN
⁴Department of Medicine, Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA
⁵Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA
⁶Center for Public Health Genomics, University of Virginia, Charlottesville, VA
⁷Department of Structural Biology, St. Jude Children´s Research Hospital, Memphis, TN

2771

B-Cell Acute Lymphoblastic Leukemia Arising in Patients with a Preexisting Diagnosis of Multiple Myeloma Is a Novel Cancer with High Incidence of TP53 Mutations

Monique Chavez, BS¹, Erica Barnell, BS²^*, Malachi Griffith, PhD³^*, Zachary Skidmore⁴^*, Obi Griffith³^*, Ling Tian, PhD⁵^* and Lukas D Wartman, MD⁶

¹Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO
²Washington University in St. Louis School of Medicine, Saint Louis, MO
³McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, Saint Louis, MO
⁴Washington University In St Louis, Saint Louis, MO
⁵Department of Medicine, Division of Oncology, Washington University School of Medicine, SAINT LOUIS, MO
⁶Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

2772

Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in Acute Myeloid Leukemia

Rasoul Pourebrahim, MD, PhD¹^*, Rafael Heinz Montoya, BS¹^*, Zoe Alaniz¹^*, Lauren B Ostermann, BS¹^*, Hung Alex Luong¹^*, Joseph D. Khoury, MD² and Michael Andreeff, MD, PhD¹

¹Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX

2773

Overexpression of hTLX3 in Association with Mutant IL7Rα Is Sufficient to Generate T-ALL In Vivo and to Transform Thymocytes in Vitro

Gisele Olinto Libanio Rodrigues, MSc¹^*, Julie Hixon¹^*, Hila Winer¹^*, Erica Matich¹^*, Caroline Andrews²^*, Sarah Cramer³^*, Wenqing Li¹^* and Scott Durum¹^*

¹National Cancer Institute, National Institutes of Health, Frederick, MD
²Charles River Laboratories, Frederick
³StageBio company, Frederick, MD

2774

NUSAP1 Promotes Cell Proliferation Via the DNA Damage Response Pathway in Diffuse Large B-Cell Lymphoma

Yang Han, MM^1,2^*, Ya Zhang, MD^1,2^*, Juan Yang, PhD^1,3^*, Jiarui Liu^1,4^*, Tan Sang^1,2^*, Shunfeng Hu, MM^1,2^*, Xinting Hu, MM^1,2^* and Xin Wang, MD, PhD^1,2

¹Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
²Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
³Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
⁴Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

2775

Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias

Yuki Nishida, MD, PhD¹, Jo Ishizawa, MD, PhD², Edward Ayoub, PhD, MS, BSc²^*, Rafael Heinz Montoya, BS²^*, Vivian Ruvolo, MS²^*, Kensuke Kojima, MD, PhD³^*, Naval Daver, MD⁴, Arnaud Lesegretain⁵^*, Sharon Shacham, PhD, MBA⁶^* and Michael Andreeff, MD, PhD²

¹Section of Molecular Hematology and Therapy, Department of Leukemia, MD Anderson Cancer Center, Houston, TX
²Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
³Department of Hematology, Kochi University Hospital, Nankoku, Japan
⁴Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
⁵Daiichi Sankyo, Inc., Basking Ridge, NJ
⁶Karyopharm Therapeutics Inc., Natick, MA

2776

Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles

Carmelo Gurnari, MD^1,2^*, Vera Adema, PhD²^*, Hassan Awada, MD², Simona Pagliuca, MD^2,3, Cassandra M Kerr, MS²^*, Sunisa Kongkiatkamon, MD²^*, Thomas Laframboise, PhD⁴^*, Valeria Visconte, PhD², Maria Teresa Voso, MD¹, Mikkael A. Sekeres, MD, MS^2,5, Hetty E. Carraway, MD, MBA^2,6, Torsten Haferlach, MD⁷ and Jaroslaw P. Maciejewski, MD, PhD⁸

¹Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
²Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
³Université de Paris, Paris, France
⁴Genetics and Genome Sciences Department, Case Western Reserve University, Cleveland, OH
⁵Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
⁶Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
⁷MLL Munich Leukemia Laboratory, Munich, Germany
⁸Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH